In recent years, studies have shown that EMAP-II plays an anti-tumor role through several processes, as the agent inhibits angiogenesis, promotes endothelial cell apoptosis and directly promotes tumor cell autophagy and apoptosis (Crippa et al., 2008; Li Z. et al., 2014; Ma et al., 2015; Chen et al., 2016). This evidence concerns the gene AIMP1 and neoplasm.